ACTIVE IMMUNOTHERAPY WITH A POLYVALENT MELANOMA VACCINE IN STAGE III

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine whether BCG, a germ found in tuberculosis, in combination with melanoma vaccine (C-VAX) is more effective than BCG and a placebo in 1) stimulation of immune response against melanoma, 2) improving overall survival, and 3) causing a delay in recurrence following surgery. This research is being done because there is no currently approved treatment for melanoma, which prolongs survival time, and no treatment of melanoma, which prolongs the time to recurrence, that does not have significant side effects. It is hoped that the combination of BCG and C-VAX, an experimental test drug will have benefits, which will help solve thi